Clinical trial

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

DDW Highlights: 14 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Eli… Read More

#Podcasts

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

This week in Drug Discovery (6 – 10 April) 

News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW.  This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Lilly has made the headlines for both an approved drug and a drug collaboration.  The top stories: … Read More

#News

#Alzheimer's #Clinical trial

Alzheon doses first patient with novel Alzheimer’s drug 

The first patient has been dosed in Alzheon’s Phase I trial of its Alzheimer’s drug.   The biopharmaceutical company dosed the patient in ALZ-507, a novel investigational oral drug candidate. The drug has been developed to target upstream amyloid aggregation and inhibit the formation of neurotoxic soluble amyloid… Read More

#News

Cancer research
#Cancer Grand Challenges #Cancer immunotherapy #CAR-T #Childhood cancer #Clinical trial

Trial to test CAR T-cell therapies as childhood cancer cures 

A first-of-its-kind trial has launched to explore whether personalised CAR T-cell immunotherapy could treat childhood cancers. The clinical trial, taking place in the UK and US, has enrolled a group of 60 children with cancer and offered them access to personalised investigational therapies. Researchers hope these investigational therapies… Read More

#Cancer Research #Editor's Choice #News

Colorectal cancer
#Clinical trial #Colorectal cancer #Prostate cancer

CuraCell doses first patient with TIL therapy 

Immunotherapy company CuraCell has dosed the first patients with its treatment for metastatic colorectal and metastatic prostate cancer.  CC-38 is novel autologous Tumour-Infiltrating Lymphocyte (TIL) therapy, currently being evaluated in Phase I/IIa trial. Up to 16 patients with Stage IV colorectal and prostate cancer will be enrolled in the trial, which will assess… Read More

#News

European Commission
#Clinical trial #European Commission #TK2d

EC grants marketing authorisation to rare disease drug 

The European Commission (EC) has granted marketing authorisation for Kygevvi (doxecitine and doxribtimine) for the treatment of thymidine kinase 2 deficiency (TK2d).  The approval, making Kygevvi the first and only treatment for TK2d, can now be used to treat paediatric and adult patients with the condition with an age of… Read More

#News #Regulatory

Osteoarthritis
#Clinical trial #Osteoarthritis

Osteoarthritis treatment could reduce pain by half 

A treatment for osteoarthritis (OA) could slash pain by half and limit stiffness and other debilitating symptoms, a study shows.  LEVI-04, developed by biotechnology company Levicept, is a first-in-class treatment for OA which led to a 50% reduction in pain for patients participating in a Phase II study. Read More

#News

Cancer patient receives chemotherapy via IV
#Clinical trial #Skin cancer

Therapeutic could help skin cancer patients avoid surgery 

A new therapeutic could help patients with non-melanoma skin cancer avoid immediate surgery, data shows.  The Phase II SkinJect dataset, released by biotech company Medicus Pharma, shows microneedle-mediated delivery of doxorubicin led to a response rate of approximately 80%.  The study, which compared doxorubicin compared with a… Read More

#Cancer Research #News

Screening patient for AMD
#Clinical trial #Geographic atrophy

First patient dosed in trial of Geographic Atrophy treatment 

The first patient has been dosed in a first-in-human clinical trial of a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).  CTx001, developed by biotechnology company Complement Therapeutics, is being evaluated in the Phase I/II Opti-GAIN study evaluating its safety, tolerability and preliminary efficacy. … Read More

#News

#Clinical trial #Evotec #Kidney cancer

Evotec to receive $10m as kidney cancer trial launches 

Evotec will receive a $10 million milestone payment as a kidney cancer trial has got underway.  Bristol Myers Squibb has launched its Phase I clinical study evaluating CELMoD agent BMS-986506, a cereblon E3 ligase modulator, in clear cell renal cell carcinoma, the most common form of kidney cancer.   The first-in-human study brings into the clinic a novel CELMoD or… Read More

#Business & Investment #News

Cancer patient receives chemotherapy via IV
#Clinical trial #Financing #Solid tumours

Mestag raises $40m to advance therapeutic cancer treatment 

Mestag Therapeutics has raised $40 million financing to advance its new therapeutic cancer treatment.  The closing of the financing round, led by life science investors SV Health Investors and Johnson & Johnson Innovation, brings total funds raised to over $95 million.  The funding is set to support the Phase I STARLYS clinical… Read More

#Business & Investment #News

Human eye
#Clinical trial #Ophthalmology #Preclinical development #Revvity

Preclinical advancements in ophthalmology drug development

Dr Jess Pesner and Caleb Proctor, Revvity, explore the use of in vivo, in vitro models, and in silico models in the quest for new treatments for diseases of the eye. Within drug and device approval paths, regulated steps protect the well-being of the public and offer hope for those who may be battling a disease or a life event that may currently not… Read More

#Exclusive Content

#Clinical trial #Infertility #Monoclonal antibodies

A new approach to treating infertility

DDW Editor Reece Armstrong speaks to Elke Bestel, Chief Medical Officer at Igyxos, about the treatment space for infertility and how the company’s monoclonal antibody IGX12 could represent a differentiated approach.   RA: Why have treatments for infertility remained limited?  EB: Developing treatments for infertility has been and is still complex. First of all, infertility can result from hormonal, anatomical, metabolic,… Read More

#Exclusive Content

#Biomarkers #Clinical trial #Genomics

Driving precision drug discovery with genomics

Dharminder Singh Chahal, Chief Executive Officer at SkylineDx, discusses the real-world applications of how SkylineDx bridges biomarker insights to therapeutic development. Real-world applications     As the healthcare landscape continues to evolve toward personalised, data-driven care, clinically validated diagnostic tests with real-world data integration are redefining how diseases are diagnosed, stratified, and treated. Recent advances in genomics have significantly reshaped the landscape of drug discovery and… Read More

#Exclusive Content

Cancer patient receives chemotherapy via IV
#Cancer research #Clinical trial #kainova #Solid tumours

Positive results announced for metastatic tumour treatment 

A new anti-tumour treatment for metastatic solid tumours has achieved encouraging results in a Phase I clinical trial.  DT-9081, developed by biopharmaceutical company Kainova Therapeutics, is a proprietary, oral small molecule EP4 receptor (EP4R) antagonist in patients with advanced, recurrent, and metastatic solid tumours.  According to Kainova, the… Read More

#Cancer Research #News

#Biomarkers #Clinical trial #Lundbeck #Neuroscience #Research and development

Are biomarkers the key to derisking neuroscience R&D?

Jesper Frank Bastlund, Senior Director in Biological and Translational Research, and Enchi Liu, Vice President, Head of Experimental Medicine at Lundbeck, examine how biomarkers can help advance the field of neuroscience.  Navigating the challenges of CNS Drug development   Neuroscience research and development has historically been one of the most challenging areas in… Read More

#Exclusive Content